IR@PKUHSC  > 北京大学口腔医学院
学科主题口腔医学
Investigation of the efficacy of a bevacizumab-cetuximab-cisplatin regimen in treating head and neck squamous cell carcinoma in mice
Wang, Yixiang1,2; Dong, Ling1,2; Bi, Qingwei3; Li, Xiao4; Wu, Dengcheng1,2; Ge, Xiyuan1,2; Zhang, Xiaoxia1,2; Fu, Jia1,2; Zhang, Chengfei5; Wang, Cunyu6; Li, Shenglin1,2
关键词Bevacizumab Cetuximab Cisplatin Chemotherapy Head And Neck Squamous Cell Carcinoma (Hnscc) Anticancer Activity
刊名TARGETED ONCOLOGY
2010-12-01
DOI10.1007/s11523-010-0164-3
5期:4页:237-243
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]METASTATIC COLORECTAL-CANCER ; ORTHOTOPIC MODEL ; TUMOR ; CHEMOTHERAPY ; PANITUMUMAB ; MECHANISMS ; PACLITAXEL ; THERAPIES ; APOPTOSIS ; ERLOTINIB
英文摘要

The efficacy of bevacizumab plus cetuximab-based chemotherapy remains unclear in head and neck squamous cell carcinoma (HNSCC). The aim of this study was to investigate the anticancer efficacy of a bevacizumab-cetuximab-cisplatin triple-agent combination in treating mouse HNSCC. SCC-VII tumor-bearing C3H mice were treated with bevacizumab, cetuximab and cisplatin either alone or in various combinations. In vivo results showed that the largest delay in tumor growth and the maximum increase in survival were not in the triple-agent combination therapy, but in the bevacizumab plus cisplatin therapy. TUNEL assay showed that the apoptosis indices in bevacizumab plus cisplatin group and a triple-agent combination group were 31.6 +/- 12.0% and 6.9 +/- 1.3%, respectively. Western blot showed that down-regulation of Bcl-2 and up-regulation of cleaved caspase-3 contributed to the anticancer effect of a triple-agent combination and bevacizumab plus cisplatin. Moreover, the maximum level of cleaved caspase-3 expression was not found in the triple-agent combination group but in the bevacizumab plus cisplatin group. Bevacizumab plus cisplatin therapy is better than bevacizumab-cetuximab-cisplatin triple therapy in the mouse HNSCC model. Our findings suggest that the bevacizumab-cetuximab-cisplatin regimen may not be suitable for treating HNSCC.

语种英语
WOS记录号WOS:000285208800003
Citation statistics
Cited Times:6[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/53754
Collection北京大学口腔医学院
北京大学口腔医学院_科研处
北京大学口腔医学院_中心实验室
作者单位1.Peking Univ, Sch Stomatol, Cent Lab, Beijing 100081, Peoples R China
2.Peking Univ, Hosp Stomatol, Cent Lab, Beijing 100081, Peoples R China
3.Hosp Oral Dis Prevent & Treatment, Dept Oral Surg, Harbin 150001, Heilongjiang, Peoples R China
4.Beijing Haidian Hosp, Dept Dent, Beijing 100080, Peoples R China
5.Univ Hong Kong, Fac Dent, Area Endodont, Hong Kong, Hong Kong, Peoples R China
6.UCLA Dent, Div Oral Biol & Med, Los Angeles, CA 90095 USA
Recommended Citation
GB/T 7714
Wang, Yixiang,Dong, Ling,Bi, Qingwei,et al. Investigation of the efficacy of a bevacizumab-cetuximab-cisplatin regimen in treating head and neck squamous cell carcinoma in mice[J]. TARGETED ONCOLOGY,2010,5(4):237-243.
APA Wang, Yixiang.,Dong, Ling.,Bi, Qingwei.,Li, Xiao.,Wu, Dengcheng.,...&Li, Shenglin.(2010).Investigation of the efficacy of a bevacizumab-cetuximab-cisplatin regimen in treating head and neck squamous cell carcinoma in mice.TARGETED ONCOLOGY,5(4),237-243.
MLA Wang, Yixiang,et al."Investigation of the efficacy of a bevacizumab-cetuximab-cisplatin regimen in treating head and neck squamous cell carcinoma in mice".TARGETED ONCOLOGY 5.4(2010):237-243.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Wang, Yixiang]'s Articles
[Dong, Ling]'s Articles
[Bi, Qingwei]'s Articles
百度学术
百度学术Similar articles in
[Wang, Yixiang]'s Articles
[Dong, Ling]'s Articles
[Bi, Qingwei]'s Articles
必应学术
必应学术Similar articles in
[Wang, Yixiang]'s Articles
[Dong, Ling]'s Articles
[Bi, Qingwei]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.